BCDA
NASDAQBioCardia Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$0.85+0.00 (+0.00%)
07:00 PM07:15 PM
News · 26 weeks64+60%
2026-01-252026-07-19
Mix4390d
- Insider23(53%)
- SEC Filings10(23%)
- Other8(19%)
- Earnings2(5%)
Latest news
25 items- INSIDERPresident and CEO Altman Peter bought $415 worth of shares (500 units at $0.83), increasing direct ownership by 0.14% to 368,885 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $3,754 worth of shares (4,300 units at $0.87), increasing direct ownership by 1% to 368,385 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $7,175 worth of shares (7,500 units at $0.96), increasing direct ownership by 2% to 369,485 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $5,208 worth of shares (5,400 units at $0.96), increasing direct ownership by 2% to 361,985 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Stertzer Simon H4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Slosman Marvin4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter covered exercise/tax liability with 54,606 shares, decreasing direct ownership by 13% to 356,585 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERChief Financial Officer Mcclung David covered exercise/tax liability with 23,125 shares, decreasing direct ownership by 17% to 114,245 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSenior Vice President, Devices Gillis Edward M covered exercise/tax liability with 17,269 shares, decreasing direct ownership by 24% to 54,126 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Blank Andrew Scott4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Allen Jim L.4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Moyes Jay M4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSEC Form 4 filed by Director Facteau Bill4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter was granted 110,625 shares, increasing direct ownership by 37% to 411,191 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERChief Financial Officer Mcclung David was granted 60,483 shares, increasing direct ownership by 79% to 137,370 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERSenior Vice President, Devices Gillis Edward M was granted 39,521 shares, increasing direct ownership by 124% to 71,395 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERDirector Stertzer Simon H bought $103,584 worth of shares (109,200 units at $0.95), increasing direct ownership by 191% to 166,338 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $2,043 worth of shares (2,300 units at $0.89), increasing direct ownership by 0.77% to 300,566 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- SECBioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Letter to Stockholders on 2026 Priorities and Strategic OpportunitiesSUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the Company's Chief Executive Officer, Peter Altman, issued the following letter to shareholders. Dear Fellow Shareholders, Upon completion of our recent capital raise, I am providing this update on our strategy, top priorities, and business development opportunities to ensure understanding and appreciation of what is ahead. This quarter, with Japan's Pharmaceutical and Medical Device Agency's (PMDA) support for potential approval of CardiAMP® Cell Therapy for the tr
- SECBioCardia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - BioCardia, Inc. (0000925741) (Filer)
- INSIDERPresident and CEO Altman Peter bought $4,250 worth of shares (5,000 units at $0.85), increasing direct ownership by 2% to 298,266 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- SECBioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Announces $4.4 Million FinancingNet proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into first commercial sales. SUNNYVALE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, sold 3,509,604 shares at an average price of $1.279 on Friday, June 5, 2026. No warrants were issued in this capital raise. About BioCardia® BioCardia, Inc., headquartered
- SECBioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
BCDA FAQ
6 questionsWhat does BioCardia Inc. do?
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery...Where does BCDA stock trade?
BioCardia Inc. (BCDA) is listed on NASDAQ.What sector and industry is BCDA in?
BioCardia Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about BCDA?
BioCardia Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $900.00 price target on 2021-12-20. Recent price targets cluster around $900.00.What companies are similar to BCDA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare BCDA side-by-side with any of them on Quantisnow.How can I track BCDA on Quantisnow?
Quantisnow aggregates BioCardia Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCDA to receive live email and push alerts on every new disclosure.